3rd Quarter - Report
STANTON PARK GROUP for BRAEBURN PHARMACEUTICALS, INC.
Firm
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HCR - HR 1629 To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs; S. 250 Fairness in Orphan Drug Exclusivity Act; reducing stigma and promoting treatment of opioid use disorder; raising awareness of the benefits of medication assisted therapy (MAT); ensuring patient access to MAT; FDA approval and exclusivity process; patient access to practitioner-administered therapies
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES DERDERIAN | — |
| VALERIE HENRY | — |
| JOSEPH RACHINSKY | — |
| ERIN STRAWN | — |
| BRYAN WILLIAM WELLS | Policy Advisor, Senator Pat Roberts |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.